Associated tags: Medicine, AP3, PKMYT1, Patient, DDR, Ovarian cancer, CHK2, WEE1, Neoplasm, Proteomics, Therapy, ACRV, Pharmaceutical industry, Conference
Locations: NEW YORK, EMORY, CHICAGO, NY, WATERTOWN, MA, US, SAR, UNITED STATES
Retrieved on:
Wednesday, April 24, 2024
Cancer,
Ovarian cancer,
RECIST,
AP3,
Trial of the century,
IND,
PKMYT1,
Dor,
Patient,
Endometrial cancer,
Medicine,
WEE1,
Event,
Neoplasm,
ACRV,
Clinical trial,
Therapy,
File,
Pharmaceutical industry WATERTOWN, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), to host a corporate R&D event. The company plans to present initial positive clinical data from the ongoing registrational-intent Phase 2 ACR-368 clinical trials, which showed prospective validation of the proprietary ACR-368 OncoSignature patient selection biomarker test with a 50% confirmed objective response rate (ORR) in patients with ovarian and endometrial cancers. Acrivon is also sharing new preclinical data for ACR-2316, now with accelerated IND filing timelines, as well as actionable findings with the machine learning-enabled AP3 platform.
Key Points:
- Acrivon is also sharing new preclinical data for ACR-2316, now with accelerated IND filing timelines, as well as actionable findings with the machine learning-enabled AP3 platform.
- “Today we present initial clinical data from our ongoing Phase 2 clinical trial which we believe highlights the power of our next generation proteomics-based AP3 precision medicine platform,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.
- Consistent with past trials, the ACR-368 treatment-related adverse event profile was predominantly reversible and transient with only mechanism-based, hematological adverse events.
- The webcast will be available for at least 30 days following the event.
Retrieved on:
Wednesday, April 17, 2024
Key Points:
- ET.
- The agenda will feature presentations by Acrivon’s leadership team followed by an interactive Q&A session.
- “We also look forward to sharing initial ACR-368 clinical data based on prospective patient responder identification with our ACR-368 OncoSignature assay, as well as preclinical updates on ACR-2316, our internally discovered, potent, single agent active WEE1/PKMYT1 inhibitor, and other pipeline progress.
- The webcast will be available for at least 30 days following the event.
Retrieved on:
Wednesday, April 10, 2024
IC50,
AP3,
Drug resistance,
Proteomics,
PDX,
CDX,
Cell cycle,
PKMYT1,
Patient,
Medicine,
WEE1,
Neoplasm,
ACRV,
AACR,
Drug development,
Biomarker,
Drug discovery,
Therapy,
Ovarian cancer,
Pharmaceutical industry WATERTOWN, Mass., April 10, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced data from two posters that the company presented at the American Association for Cancer Research (AACR) Annual Meeting.
Key Points:
- “Uniquely enabled by AP3, we designed a selective and potent dual inhibitor of both WEE1 and PKMYT1, ACR-2316, designed for potent single agent activity.
- We presented preclinical data showing its superior activity versus benchmark WEE1 and PKMYT1 single-agent inhibitors in multiple cancer models and look forward to advancing this compound into the clinic.
- The complete responses observed with ACR-2316 in human tumor xenograft mouse models were associated with strong WEE1 and balanced PKMYT1 inhibition activity in tumors.
- This corresponded with the subsequent upregulation of ACR-368 OncoSignature biomarkers, indicating that the OncoSignature assay can predict which ULDG sensitized tumors would be responsive to treatment with ACR-368.
ACRV,
Exchange,
Health,
Intelligence,
Patient,
Neoplasm,
Paradigm,
Research,
AP3,
Sale,
Security (finance),
Prospectus,
Investment,
Therapy,
PIPE,
Jefferies,
Machine learning,
Medicine Acrivon anticipates the gross proceeds from the oversubscribed PIPE to be approximately $130 million, before deducting fees to the placement agent and other offering expenses payable by the company.
Key Points:
- Acrivon anticipates the gross proceeds from the oversubscribed PIPE to be approximately $130 million, before deducting fees to the placement agent and other offering expenses payable by the company.
- The closing of the financing is expected to occur on April 11, 2024, subject to customary closing conditions.
- “We are excited to announce this financing and thank our new and key existing investors who have shown their support for and confidence in Acrivon,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.
- Jefferies acted as the exclusive placement agent in the private placement.
WEE1,
Research,
ACRV,
Ovarian cancer,
Carcinoma,
Drug discovery,
Patient,
Neoplasm,
Cell cycle,
AP3,
IC50,
Proteomics,
Abstract,
AACR,
PKMYT1,
Clinical trial,
Therapy,
Toxicology,
Mass spectrometry,
GLP,
Medicine,
LDG,
Pharmaceutical industry “On the heels of a productive 2023, we are off to a tremendous start in 2024, which is an important and data-driven year for Acrivon,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon.
Key Points:
- “On the heels of a productive 2023, we are off to a tremendous start in 2024, which is an important and data-driven year for Acrivon,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon.
- We remain on track to present more mature clinical data during the first half of 2024.
- Additionally, our novel WEE1/PKMYT1 inhibitor ACR-2316 continues to demonstrate robust and superior single-agent preclinical activity and tolerability as demonstrated in head-to-head benchmark studies.
- As of December 31, 2023, the company had cash, cash equivalents and marketable securities of $127.5 million, which is expected to fund operations into the fourth quarter of 2025.
Drug resistance,
Neoplasm,
Drug design,
AACR,
Therapy,
Patient,
ACRV,
Medicine,
AP3,
PKMYT1,
WEE1,
Gemcitabine,
Pharmaceutical industry WATERTOWN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced the company will be presenting data at the American Association for Cancer Research (AACR) Annual Meeting taking place April 5 – 10, 2024 in San Diego, CA.
Key Points:
- “The data we will be presenting reinforce the broad applicability of our highly differentiated, actionable AP3 platform technology,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.
- “ACR-2316 is our first fully internally-discovered development candidate which was rapidly generated through co-crystallography-based drug design and uniquely leverages AP3.
- Our platform enables us to generate selective, potent single-agent active molecules, such as ACR-2316, that we believe can address some of the key limitations of current WEE1 and PKMYT1 inhibitors.
- We look forward to presenting these two datasets at AACR next month.”
Gene editing,
Takeda Pharmaceutical Company,
Neoplasm,
Investment,
Pfizer,
Drug discovery,
University,
CFA,
New Enterprise Associates,
Proteomics,
Doctor of Philosophy,
NEA,
Therapy,
Patient,
Radiopharmaceutical,
ACRV,
Medicine,
AP3,
Texas A&M University,
Chemical engineering,
Columbia University,
Cowen Inc.,
Research,
PFM,
Biochemistry,
Pharmaceutical industry Dr. Palani added, “Acrivon is an entirely science-based company and its AP3 platform is a ground-breaking approach which is broadly applicable across drug discovery and development with significant unrealized potential -- not only in oncology but also in other areas including autoimmune and metabolic disorders, as dysregulated signaling ultimately underlies all diseases. The company currently is focused on oncology with a highly differentiated profile in this space. I am excited to join a distinguished board and support the full realization of the potential of the platform applied to the company’s current pipeline and beyond.”
Key Points:
- “Santhosh previously served as an advisor to Acrivon and has a deep understanding and appreciation of the breadth and novelty of our next generation precision medicine platform,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.
- At PFM, Dr. Palani led public and private biotechnology investments, and served on the board of companies in the cell therapy and gene editing fields.
- Prior to Cowen, Dr. Palani was in oncology drug development at Pfizer Inc. and Takeda Pharmaceuticals.
- I am excited to join a distinguished board and support the full realization of the potential of the platform applied to the company’s current pipeline and beyond.”
Retrieved on:
Tuesday, February 27, 2024
WATERTOWN, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced the company’s president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a panel entitled “Gynecological Cancers Corporate Panel Discussion” on Tuesday, March 5, 2024 at 10:30 a.m.
Key Points:
- WATERTOWN, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced the company’s president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a panel entitled “Gynecological Cancers Corporate Panel Discussion” on Tuesday, March 5, 2024 at 10:30 a.m.
- ET at the TD Cowen 44th Annual Health Care Conference in Boston, MA.
- To access the live webcast, visit the Events & Presentations page within the investor section of the company’s website at https://ir.acrivon.com/news-events/events-presentations .
- A replay of the webcast will be available via the same link for 30 days following the event.
Retrieved on:
Thursday, February 8, 2024
Wheaton College,
Neoplasm,
Research,
Harvard University,
Genetics,
Patient,
Head,
IPO,
Chemistry,
Doctor of Philosophy,
AP3,
Senior counsel,
Applied Genetic Technologies Corporation,
Ipsen,
Therapy,
ACRV,
Medicine,
Proteomics,
Suffolk University Law School,
Biology,
IP,
Teva Pharmaceuticals,
Management “We are excited to welcome Ivana to our board of directors,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.
Key Points:
- “We are excited to welcome Ivana to our board of directors,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.
- Under her strong leadership, Vigil has evolved from inception through IPO, to an organization with two clinical-stage development programs.
- Dr. Magovčević-Liebisch has served on the Board of Directors of Absci, Aeglea Therapeutics and Applied Genetic Technologies Corporation.
- I look forward to working with Peter, the board, and the executive team to develop multiple promising drug candidates to improve patient lives.”
Retrieved on:
Tuesday, February 6, 2024
WATERTOWN, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced the company’s president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Tuesday, February 13, 2024 at 2:40 p.m.
Key Points:
- WATERTOWN, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced the company’s president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Tuesday, February 13, 2024 at 2:40 p.m.
- ET at the Oppenheimer 34th Annual Healthcare Life Sciences Conference.
- To access the live webcast, visit the Events & Presentations page within the investor section of the company’s website at https://ir.acrivon.com/news-events/events-presentations.
- A replay of the webcast will be available via the same link for 30 days following the event.
